Elsevier

Pharmacological Research

Volume 129, March 2018, Pages 274-294
Pharmacological Research

Review
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials

https://doi.org/10.1016/j.phrs.2017.12.001Get rights and content

Abstract

Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a relatively new class of non-insulin glucose-lowering agents, belonging to the incretin family, which are able to improve glycemic control with a favorable safety profile, since they are associated with a low risk of hypoglycemia, no weight gain, and good tolerability in patients with chronic renal failure. Some experimental and clinical studies suggest that these drugs may exert significant pleiotropic effects, in particular on chronic kidney disease (CKD) progression, but data from clinical trials are still controversial. In an effort to clarify the effects of DPP-4 inhibitors (DPP-4is) on diabetes-related renal damage, we performed a narrative review of available clinical trials and other experimental studies focusing on renal effects of DPP-4is. Currently, there is no conclusive evidence proving the usefulness of this drug class for improving diabetes-related renal damage. However, our literature review suggests that DPP-4is are safe and well tolerated in type 2 diabetes mellitus (T2DM) patients with CKD. More importantly, results from the reviewed studies indicate that DPP-4 inhibitor therapy may improve two major risk factors for diabetic nephropathy, such as hyperglycemia and albuminuria, resulting in potential renal benefits beyond glycemic control. Despite several limitations, the conclusions of our review corroborate previous evidence on the potential renal benefits of DPP-4is, highlighting the urgent need of future trials adequately powered and designed on hard renal outcomes to ascertain (or contradict) the therapeutic benefit of DPP-4is in T2DM and CKD patients.

Introduction

Diabetes mellitus (DM) is a multifactorial disease [1] associated with serious comorbidities. This condition has recently reached epidemic proportions, as its occurrence has exponentially increased in the general population. Over 400 million people worldwide were estimated to have DM and total mortality increased by 32.1% from 2005 to 2015. Diabetes caused 5 million deaths in 2015, representing the seventh leading cause of death in the United States [[2], [3]]. Moreover, the risk of both microvascular and macrovascular complications has significantly increased, including diabetic kidney disease (DKD), an independent risk factor for coronary artery and peripheral vascular disease. Hyperglycemia triggers many mechanisms resulting in alteration of kidney architecture, oxidative and inflammatory stress, and eventually progressive loss of renal function [[4], [5]].

Strict glucose control through lifestyle changes (i.e., diet, physical exercise, and weight loss) is crucial for slowing DKD progression. However, most type 2 diabetic patients need also medications such as oral hypoglycemic agents and insulin to achieve sustained control of hyperglycemia [6]. Other pharmacological treatments have a positive effect on renal function, retarding the evolution to end-stage renal disease (ESRD) [7]. For instance, renin–angiotensin system (RAS) inhibitors [8] as well as the use of antioxidant agents [9] have demonstrated significant renoprotection, particularly related to their anti-proteinuric activity. Interestingly, the anti-inflammatory and hemorrheologic drug pentoxifylline may also afford renoprotective effects, even though there is still no conclusive evidence supporting its widespread use for improving renal outcomes in subjects with chronic kidney disease (CKD) of various etiology [10]. Some drugs specifically used to treat diabetes, like incretin-based therapies, represent a relatively new tool against the global epidemic of DM. Incretin-based drugs include glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and inhibitors of dipeptidyl-peptidase-4 (DPP-4). They basically promote a significant decrease in serum glucose that is accompanied by low risk of hypoglycemia and weight loss (with GLP-1RAs) or weight neutrality (with DPP-4 inhibitors) when compared to conventional therapies (metformin monotherapy or combination therapy) [[11], [12]]. However, conflicting results have been obtained with these drugs: some clinical studies, in fact, have shown positive pleiotropic effects in retarding DKD [[13], [14], [15], [16]], whereas others pointed out the possible accumulation of these agents in patients with impaired renal function, thereby exposing them to adverse events [[17], [18], [19], [20], [21], [22]].

In the first part of this review, we describe the incretin system, explaining its main physiological and pathophysiological characteristics and discussing the pleiotropic effects of DPP-4 inhibitor therapy, particularly with regard to renal protection. We then report on pre-clinical results in animal models, followed by evidence on the progression or regression of renal damage following DPP-4 inhibitor therapy obtained by an analysis of clinical studies.

Section snippets

Main pharmacologic features of DPP-4 inhibitors: an overview

Drugs that inhibit DPP-4 activity, commonly referred to as gliptins, represent a relatively new class of non-insulin glucose-lowering agents endowed with great ability to improve glycemic control, with a favorable tolerability and safety profile [[23], [24]]. DPP-4 belongs to a family of proteolytic enzymes that are ubiquitously expressed in several tissues where they exert different functions. In particular, the DPP-4 enzyme exists in two forms, a soluble form circulating in the blood and a

Pleiotropic effects of DPP-4 inhibitors beyond glycemic control

Beyond the pancreas, GLP-1R and DPP-4 are expressed in a wide variety of organs and tissues, such as the central and peripheral nervous system, heart, lung, gastrointestinal tract, eye and kidney, thereby explaining the pleiotropic effects of the incretin system [[43], [44], [45]]. Some of these extra-pancreatic effects might be exploited to prevent or treat diabetes-related complications, independently of the achievement of glycemic control. Accordingly, GLP-1 has been shown to prevent

Effects of DPP-4 inhibitors on kidney function: physiological settings

GLP-1 signaling mediates important renal functions [101], as suggested by the expression of both DPP-4 and GLP-1R in the kidney of several species, including humans [102]. However, controversial data exists on the specific expression pattern of these proteins, based on the specificity and sensitivity of detection methods [[88], [103]]. Few studies suggest their presence in the renal blood vessels, glomerular cells and tubular cells [102]. Studies on rodents show that DPP-4 is extensively

Potential benefits of DPP-4 inhibition in diabetic kidney disease (DKD)

The above preclinical and clinical evidence of gliptin-related renoprotective actions beyond glycemic control might account for the potential ability of DPP-4 inhibition to improve the pathophysiological processes leading to DKD. Although hyperglycemia, increased intra-glomerular pressure, and hyperfiltration are key players in the pathogenesis of DN [101], accruing evidence indicates that alternative mechanisms, including the enhanced production of inflammatory cytokines and ROS, advanced

Clinical evidence of renal benefits or detriments of DPP-4 inhibitors from randomized controlled clinical trials

The clinical impact of DPP-4is on renal outcomes represents a timely and controversial issue, as findings from various clinical studies are somewhat conflicting. In order to catch the most relevant evidence on this topic, we approached the existing literature by using predefined search criteria (see below) in order to find the most relevant randomized controlled trials (RCTs) and meta-analyses dealing with the effects of these agents on renal outcomes in individuals with evidence of renal

Conclusions

DPP-4is are among the most used and effective oral antidiabetic agents. They have many advantages, including high glucose-lowering potency, low risk of hypoglycemia, no association with weight gain, and tolerability by chronic renal failure patients. However, their efficacy for preventing diabetic complications, especially DN, is not well established.

In summary, diabetes management is complex, multi-dimensional and potentially expensive in patients with T2DM and renal insufficiency. Our

Conflict of interest

The Authors declare no conflict of interest related to the present work

References (194)

  • L. Han et al.

    Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways

    Diabetes Res. Clin. Pract.

    (2012)
  • A. Shiraki et al.

    The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells

    Atherosclerosis

    (2012)
  • M. Terasaki et al.

    Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice

    Metabolism

    (2012)
  • S. Maeda et al.

    Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats

    Int. J. Cardiol.

    (2012)
  • N. Satoh-Asahara et al.

    A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients

    Metabolism

    (2013)
  • G.G. Sokos et al.

    Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

    J. Card. Fail.

    (2006)
  • B. Hocher et al.

    The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats

    Int. J. Cardiol.

    (2013)
  • H.Y. Jin et al.

    Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats

    Arch. Med. Res.

    (2009)
  • Z. Fu et al.

    Protection of exenatide for retinal ganglion cells with different glucose concentrations

    Peptides

    (2012)
  • C.R. Pullinger et al.

    Evidence that an HMGA1 gene variant associates with type 2 diabetes, body mass index, and high-density lipoprotein cholesterol in a Hispanic-American population

    Metab. Syndr. Relat. Disord.

    (2014)
  • International Diabetes Federation Diabetes Atlas

    (2015)
  • G.B.D. Mortality et al.

    Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

    Lancet

    (2016)
  • C. Leporini et al.

    Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013–2016) analysis

    Expert Opin. Drug Saf.

    (2016)
  • V. Lacava et al.

    Novel avenues for treating diabetic nephropathy: new investigational drugs

    Expert Opin. Investig. Drugs

    (2017)
  • D. Bolignano et al.

    The dark side of blocking RAS in diabetic patients with incipient or manifested nephropathy

    Exp. Clin. Endocrinol. Diabetes

    (2016)
  • D. Bolignano et al.

    Antioxidant agents for delaying diabetic kidney disease progression: a systematic review and meta-analysis

    PLoS One

    (2017)
  • T. Karagiannis et al.

    Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

    BMJ

    (2012)
  • B.M. Scirica et al.

    Investigators, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

    N. Engl. J. Med.

    (2013)
  • H. Fujita et al.

    DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathy

    Endocr. J.

    (2014)
  • S. Imamura et al.

    The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients

    Tohoku J. Exp. Med.

    (2013)
  • H. Linnebjerg et al.

    Effect of renal impairment on the pharmacokinetics of exenatide

    Br. J. Clin. Pharmacol.

    (2007)
  • B. Gallwitz

    Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors

    Ther. Adv. Endocrinol. Metab.

    (2013)
  • A.J. Scheen

    Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

    Diabetes Obes. Metab.

    (2010)
  • W.J. Weise et al.

    Exenatide-associated ischemic renal failure

    Diabetes Care

    (2009)
  • Y. Kaakeh et al.

    Liraglutide-induced acute kidney injury

    Pharmacotherapy

    (2012)
  • T.D. Filippatos et al.

    Effects of glucagon-like peptide-1 receptor agonists on renal function

    World J. Diabetes

    (2013)
  • A.J. Scheen

    Cardiovascular effects of gliptins, nature reviews

    Cardiology

    (2013)
  • G. Schernthaner et al.

    The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system

    Diabetes Vasc. Dis. Res.

    (2014)
  • A.M. Lambeir et al.

    Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV

    Crit. Rev. Clin. Lab. Sci.

    (2003)
  • A.L. Sun et al.

    Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease

    Diabetes Vasc. Dis. Res.

    (2012)
  • D.J. Drucker

    Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action

    Diabetes Care

    (2007)
  • M.A. Nauck et al.

    Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients

    Diabetologia

    (1993)
  • T. Vilsboll et al.

    The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

    J. Clin. Endocrinol. Metab.

    (2003)
  • T. Vilsboll et al.

    Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients

    Diabetes

    (2001)
  • C.F. Deacon et al.

    Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

    Diabetes

    (1995)
  • S.C. Liu et al.

    Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis

    Diabetes Obes. Metab.

    (2012)
  • S.A. Amiel et al.

    Hypoglycaemia in type 2 diabetes

    Diabetic Med.

    (2008)
  • L.K. Golightly et al.

    Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

    Clin. Pharmacokinet.

    (2012)
  • S. Retlich et al.

    Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg–10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects

    Clin. Pharmacokinet.

    (2010)
  • C.Y. Wu et al.

    Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system

    Pharm. Res.

    (2005)
  • Cited by (0)

    1

    These two Authors equally contributed to the present work

    View full text